Literature DB >> 23296111

Breast cancer in 2012: New drugs, new knowledge, new targets.

Mariana Chavez-MacGregor1, Ana Maria Gonzalez-Angulo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23296111     DOI： 10.1038/nrclinonc.2012.236

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  10 in total

1.  Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

Authors:  José Baselga; Javier Cortés; Sung-Bae Kim; Seock-Ah Im; Roberto Hegg; Young-Hyuck Im; Laslo Roman; José Luiz Pedrini; Tadeusz Pienkowski; Adam Knott; Emma Clark; Mark C Benyunes; Graham Ross; Sandra M Swain
Journal:  N Engl J Med       Date:  2011-12-07       Impact factor: 91.245

2.  Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

Authors:  José Baselga; Mario Campone; Martine Piccart; Howard A Burris; Hope S Rugo; Tarek Sahmoud; Shinzaburo Noguchi; Michael Gnant; Kathleen I Pritchard; Fabienne Lebrun; J Thaddeus Beck; Yoshinori Ito; Denise Yardley; Ines Deleu; Alejandra Perez; Thomas Bachelot; Luc Vittori; Zhiying Xu; Pabak Mukhopadhyay; David Lebwohl; Gabriel N Hortobagyi
Journal:  N Engl J Med       Date:  2011-12-07       Impact factor: 91.245

3.  A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.

Authors:  Ian E Krop; Patricia LoRusso; Kathy D Miller; Shanu Modi; Denise Yardley; Gladys Rodriguez; Ellie Guardino; Michael Lu; Maoxia Zheng; Sandhya Girish; Lukas Amler; Eric P Winer; Hope S Rugo
Journal:  J Clin Oncol       Date:  2012-05-29       Impact factor: 44.544

Review 4.  Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer.

Authors:  Todd W Miller; Justin M Balko; Carlos L Arteaga
Journal:  J Clin Oncol       Date:  2011-10-17       Impact factor: 44.544

5.  Trastuzumab emtansine for HER2-positive advanced breast cancer.

Authors:  Sunil Verma; David Miles; Luca Gianni; Ian E Krop; Manfred Welslau; José Baselga; Mark Pegram; Do-Youn Oh; Véronique Diéras; Ellie Guardino; Liang Fang; Michael W Lu; Steven Olsen; Kim Blackwell
Journal:  N Engl J Med       Date:  2012-10-01       Impact factor: 91.245

6.  Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.

Authors:  Howard A Burris; Hope S Rugo; Svetislava J Vukelja; Charles L Vogel; Rachel A Borson; Steven Limentani; Elizabeth Tan-Chiu; Ian E Krop; Richard A Michaelson; Sandhya Girish; Lukas Amler; Maoxia Zheng; Yu-Waye Chu; Barbara Klencke; Joyce A O'Shaughnessy
Journal:  J Clin Oncol       Date:  2010-12-20       Impact factor: 44.544

7.  Molecular portraits of human breast tumours.

Authors:  C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

8.  Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy.

Authors:  José Baselga; Karen A Gelmon; Shailendra Verma; Andrew Wardley; Pierfranco Conte; David Miles; Giulia Bianchi; Javier Cortes; Virginia A McNally; Graham A Ross; Pierre Fumoleau; Luca Gianni
Journal:  J Clin Oncol       Date:  2010-02-01       Impact factor: 44.544

9.  Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study.

Authors:  Thomas Bachelot; Céline Bourgier; Claire Cropet; Isabelle Ray-Coquard; Jean-Marc Ferrero; Gilles Freyer; Sophie Abadie-Lacourtoisie; Jean-Christophe Eymard; Marc Debled; Dominique Spaëth; Eric Legouffe; Djelila Allouache; Claude El Kouri; Eric Pujade-Lauraine
Journal:  J Clin Oncol       Date:  2012-05-07       Impact factor: 44.544

10.  Comprehensive molecular portraits of human breast tumours.

Authors: 
Journal:  Nature       Date:  2012-09-23       Impact factor: 49.962
  10 in total
  4 in total

1.  MiR-125b regulates epithelial-mesenchymal transition via targeting Sema4C in paclitaxel-resistant breast cancer cells.

Authors:  Qingling Yang; Yangyang Wang; Xiaohui Lu; Zunlan Zhao; Lihua Zhu; Sulian Chen; Qiong Wu; Changjie Chen; Zhiwei Wang
Journal:  Oncotarget       Date:  2015-02-20

2.  Acquisition of epithelial-mesenchymal transition is associated with Skp2 expression in paclitaxel-resistant breast cancer cells.

Authors:  Q Yang; J Huang; Q Wu; Y Cai; L Zhu; X Lu; S Chen; C Chen; Z Wang
Journal:  Br J Cancer       Date:  2014-03-18       Impact factor: 7.640

3.  The expression and clinical significance of HERC4 in breast cancer.

Authors:  Hui Zhou; Rong Shi; Min Wei; Wen-Ling Zheng; Jue-Yu Zhou; Wen-Li Ma
Journal:  Cancer Cell Int       Date:  2013-11-14       Impact factor: 5.722

4.  Survivin family proteins as novel molecular determinants of doxorubicin resistance in organotypic human breast tumors.

Authors:  Alice Faversani; Valentina Vaira; Giacomina P Moro; Delfina Tosi; Alessia Lopergolo; David C Schultz; Dayana Rivadeneira; Dario C Altieri; Silvano Bosari
Journal:  Breast Cancer Res       Date:  2014-05-30       Impact factor: 8.408
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.